Drug news
Valeant Pharma to market Halaven for Breast Cancer in Eastern Europe
Valeant Pharma (Swiss division) will distribute Halaven (eribulin) from Eisai in Bulgaria, Estonia, Latvia, Lithuania, Poland, Romania, Hungary and Slovenia for the treatment of patients with metastatic Breast Cancer whose disease has progressed after at least two chemotherapeutic regimens. Halaven is approved in the USA and EU.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.